Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.)
- PMID: 6280332
Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.)
Abstract
A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31 patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not the a fibrinolysis activator (theophylline nicotinate). Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.
Similar articles
-
Activation of platelets and of fibrinolysis by venous occlusion in healthy volunteers and influence of suloctidil in comparison with placebo.Arzneimittelforschung. 1983;33(8):1203-5. Arzneimittelforschung. 1983. PMID: 6315025 Clinical Trial.
-
Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.Pharmatherapeutica. 1985;4(6):399-404. Pharmatherapeutica. 1985. PMID: 3001778 Clinical Trial.
-
Effect of suloctidil on platelet function in patients with shortened platelet survival time.Thromb Res. 1984 Aug 15;35(4):397-406. doi: 10.1016/0049-3848(84)90231-7. Thromb Res. 1984. PMID: 6091290 Clinical Trial.
-
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.Agents Actions Suppl. 1984;15:173-87. Agents Actions Suppl. 1984. PMID: 6091423 Review. No abstract available.
-
Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.Clin Appl Thromb Hemost. 2007 Jul;13(3):299-307. doi: 10.1177/1076029607302561. Clin Appl Thromb Hemost. 2007. PMID: 17636192 Review.
Cited by
-
Effect of suloctidil on rat liver.Arch Toxicol. 1986 Jul;59(2):115-20. doi: 10.1007/BF00286734. Arch Toxicol. 1986. PMID: 3019276
-
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.BMJ. 1994 Jan 8;308(6921):81-106. BMJ. 1994. PMID: 8298418 Free PMC article.
-
Antiplatelet agents for the treatment of deep venous thrombosis.Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD012369. doi: 10.1002/14651858.CD012369.pub2. Cochrane Database Syst Rev. 2022. PMID: 35876829 Free PMC article.